Nordic Nanovector AS: The Board Appoints Mr. Luigi Costa as New CEO

  Nordic Nanovector AS: The Board Appoints Mr. Luigi Costa as New CEO

Business Wire

OSLO, Norway -- August 26, 2014

Regulatory News:

The Board of Nordic Nanovector is pleased to announce the appointment of Mr.
Luigi Costa as new CEO of the Company.

Mr. Costa has over 20 years of international pharmaceutical and biotech
experience. Most recently he held the position of Vice President Europe,
Middle East and Africa for Onyx Pharmaceuticals, a global biopharmaceutical
company based in South San Francisco, California. He was responsible for the
startup of the Company’s international organization and for the pre-launch and
launch of its Hematology potential blockbuster Kyprolis outside the US.

Prior to joining Onyx Pharmaceuticals, he held several roles of increasing
responsibility with Amgen including Head of International Oncology Franchise,
General Manager of Italy and Vice President and General Manager of France, the
Company’s largest market outside the US.

Mr. Costa started his career in the pharmaceutical industry at Eli Lilly in
Italy followed by 5 years at the Company’s US headquarters, where after
leading the CNS Sales South Region, he headed Global Pricing and Access for
the CNS portfolio.

Mr. Costa, is a highly successful senior commercial bio-pharma/'biotech'
leader in Europe. He has delivered a track record across diverse products and
therapeutic areas with experience gained on both sides of the Atlantic.

He holds a Bachelor’s degree in Business Administration from the University of
Parma, and an MBA from SDA Bocconi in Milan. He currently resides near Zurich,
Switzerland and is an active member of Help for Hope, a nonprofit organization
with the mission to help children in need around the world
( Mr. Luigi Costa will take over as CEO on the 1st
September 2014.

”We are about to enter a new and more international phase in the development
of Nordic Nanovector. The Board is therefore pleased that Mr. Luigi Costa has
accepted to take over the helm as CEO and take the Company to its new phase,”
says Chairman Roy H. Larsen on behalf of the Board. ”We see this as yet
another professional acknowledgement of the Company and its product
Betalutin’s future potential.”

”We are grateful for Jan A. Alfheim’s personal commitment and contributions as
CEO in building up the organization of the Company in the first years of its
lifetime” says Roy H. Larsen.

About Nordic Nanovector AS

Nordic Nanovector AS is a privately held company established in 2009. The
company is based in Norway and has offices and laboratories in Oslo. The
company is developing novel innovative anticancer radioimmunotherapeutics to
treat non-Hodgkin Lymphoma (NHL) and other hematological malignancies.

About Betalutin

Betalutin™, is a pharmaceutical product candidate consisting of a radionuclide
conjugated to a tumor seeking carrier/antibody, which can be used for
irradiation of malignant metastasized tumors with minimal damage to nearby
healthy normal tissue. This technology aims to prolong and improve the quality
of life of people who suffer from non-Hodgkin Lymphoma (NHL).

This information was brought to you by Cision


Nordic Nanovector AS
Roy H. Larsen
Chairman of the Board
Phone:( 47) 22 18 33 02
Cell: ( 47) 92 01 64 87
Press spacebar to pause and continue. Press esc to stop.